Welcome to isctr.org
ISCTR - TCT 2017 Consensus Summit
Building on the success of last year’s symposium, the ISCTR Board of Directors invite you to the ISCTR – TCT 2017 Consensus Summit on Clinical Endpoints/Surrogates and Effect Size for Approval of Cardiovascular Devices, being held Sunday, October 29, 2017, in Denver, Colorado. Presenting the Keynote Address will be Sir Professor Magdi Yacoub, MD, FRS, OM, who will be speak on Ventricular Assist Devices: The Windy Road to Recovery.
The International Liaison to the ISCTR Governing Board, Dr. Yacoub is Professor of Cardiothoracic Surgery at the National Heart and Lung Institute, Imperial College London, and Founder and Director of Research at the Harefield Heart Science Centre, where he oversees more than 60 scientists and students in the areas of tissue engineering, myocardial regeneration, stem cell biology, end stage heart failure and transplant immunology. He is also Founder and Director of Magdi Yacoub Research Network which has created the Qatar Cardiovascular Research Center. In addition, he founded the Aswan Heart Center to be the hub of the Middle East for advanced adult and congenital cardiac surgery.
Professor Yacoub was born in Egypt and graduated from Cairo University Medical School in 1957, trained in London, and held an assistant professorship at the University of Chicago. He also has served as a professor of cardiothoracic surgery for more than 20 years and was a consultant cardiothoracic surgeon at Harefield Hospital from 1969-2001 and Royal Brompton Hospital from 1986-2001. Professor Yacoub established the largest heart and lung transplantation program in the world where more than 2,500 transplant operations have been performed. He has also developed novel operations for a number of complex congenital heart anomalies. He was knighted for his services to medicine and surgery in 1991, awarded Fellowship of the Academy of Medical Sciences in 1998 and Fellowship of The Royal Society in 1999. More information about Dr. Yacoub is available here.
Update: Consensus Strategies for Device Development for Cardiovascular Disease
Based on the conversations begun at our consensus summit at the 2016 TCT meeting, ISCTR is collaborating with innovators, regulators, industry leaders, and others to create strategies and methodologies designed to achieve the rapid and cost-effective translation of cardiovascular device advances into clinical practice.
Working groups comprised of experts in the their field have been formed to focus on specific areas of device development and implementation. The group dedicated to an overview of the translational pathway is being chaired by David R. Holmes, Jr., MD, MACC, while separate groups will concentrate on breaking down the methodologies involved in the development of aortic/pulmonic valves, led by Stanton Rowe; mitral/tricuspid valves, headed by Michael Mack, MD, FACC; stents, steered by Charles Simonton, MD, FACC; and catheter ablation devices, led by Douglas Packer, MD. These groups have been developing their sections and we expect to convene a meeting at the Food and Drug Administration this fall to review their critical efforts.
Check back often to get more details about this meeting and the development of the documentation of these strategies as they are available. You can learn more about the genesis of this meeting through our coverage of our 2016 TCT summit here.
ESC Congress 2017
ISCTR President Nabil Dib, MD, MSc, FACC
presented “The Optimal Process of Translating Basic Innovations into Clinical Care” during a session on Developments in Cardiovascular Translation Research that also featured Eugene Braunwald, MD, MACC, MACP, ISCTR Vice President Anthony DeMaria, MD, MACC, and ISCTR Board Member Robert Roberts, MD, FACC.
View presentations from the 9th Annual ISCTR Symposium
Become an ISCTR Member
An ISCTR member publication
International Society for
Cardiovascular Translational Research
The International Society for Cardiovascular Translational Research (ISCTR) is a non-profit organization that was founded in 2007 by Dr Nabil Dib with a goal to expedite scientific discovery to clinical application (patients).